Tyme Technologies Inc
F:RFL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Tyme Technologies Inc
Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. The company is headquartered in Bedminster, New Jersey and currently employs 17 full-time employees. The company went IPO on 2012-05-25. The firm is focused on developing cancer metabolism-based therapies (CMBTs) for a range of solid tumors and hematologic cancers. The firm's lead clinical CMBT compound, SM-88, is an oral investigational modified tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cell's key defenses and leading to cell death through oxidative stress and exposure to the body's natural immune system. The company is also developing SM-88i, an injectable formulation of SM-88 for the treatment of multiple oncology indications. Its TYME-18, is a pre-clinical CMBT designed for the intra-tumoral delivery of the treatment and increase the permeability of cancer cells, while delivering a therapy having selective cytotoxic effect on the tumor. Its TYME-19, is an oral, synthetically produced member of the bile acid family that is being developed for the potential treatment of COVID-19.
Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. The company is headquartered in Bedminster, New Jersey and currently employs 17 full-time employees. The company went IPO on 2012-05-25. The firm is focused on developing cancer metabolism-based therapies (CMBTs) for a range of solid tumors and hematologic cancers. The firm's lead clinical CMBT compound, SM-88, is an oral investigational modified tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cell's key defenses and leading to cell death through oxidative stress and exposure to the body's natural immune system. The company is also developing SM-88i, an injectable formulation of SM-88 for the treatment of multiple oncology indications. Its TYME-18, is a pre-clinical CMBT designed for the intra-tumoral delivery of the treatment and increase the permeability of cancer cells, while delivering a therapy having selective cytotoxic effect on the tumor. Its TYME-19, is an oral, synthetically produced member of the bile acid family that is being developed for the potential treatment of COVID-19.
